Safety and Tolerability

A treatment's value depends as much on its safety and tolerability as on its efficacy, and this is an area where light-based therapy has practical advantages. This page summarises the profile of the two modalities and the framework that supports their safe use.

A favourable overall profile

LM™ LLLT photobiomodulation is non-invasive and non-thermal, with no incision and no tissue ablation. As Professor James Wolffsohn has noted in describing his own early adoption, low-level light therapy has a favourable safety profile with no absolute contraindications identified, which is especially valuable in patients already managing multiple medications. The treatment is painless, requires no anaesthesia and has no downtime, which also supports the adherence that chronic-disease therapy depends on.

IPL-specific considerations

OPE™ IPL delivers light to the skin and therefore warrants additional care. Photosensitising medications and a personal history of photosensitivity reactions matter, and screening before treatment is part of good practice. The gel-free, self-modulating design keeps energy within a skin-safe range and widens applicability, but it does not remove the need for that screening.

Adverse events are rare and usually preventable

Across the platform, adverse events are uncommon, and where they occur they are predominantly attributable to incorrect mask positioning or to undisclosed photosensitisers rather than to the technology itself. Correct technique, a complete medication and photosensitivity history, and adherence to the device Instructions for Use are the practical safeguards.

Recent controlled trials reinforce this profile in new settings. In the posterior segment, the 12-month randomised DRUSEN trial reported no retinal phototoxicity and a lower overall rate of ocular adverse events in the PBM group than in sham (Iovino et al., 2026, British Journal of Ophthalmology). In refractive surgery, perioperative use around Femto-LASIK produced no treatment-related adverse events (Solarino et al., 2026, Therapeutic Advances in Ophthalmology).

The honest limits of the literature

The TFOS DEWS III report is explicit that the contraindication and precaution literature for both LLLT and IPL is not exhaustively defined (TFOS DEWS III, 2025, American Journal of Ophthalmology). The appropriate response is not overconfidence but good clinical governance: informed consent, review of the device IFU, and clinical judgement. This is also why professional oversight is integral to Espansione's model and why a regulated medical device differs fundamentally from a consumer light gadget. See also safety by design.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.